• OUR DATA
  • BUY REPORTS & LISTS
  • OUR BLOG
 

Trius Therapeutics, Inc. Marketing Contacts

Trius Therapeutics is an early-stage biopharmaceutical company developing antibiotics to treat life-threatening bacterial infections. Torezolid phosphate, its lead candidate, is an IV- and orally-administered antibiotic being studied for its potential to treat antibiotic-resistant strains of staph infection, known as MRSA (methicillin-resistant Staphylococcus aureus). The company will market torezolid phosphate to hospitals and other health care providers if and when it is approved by the FDA. Trius went public in 2010 through an IPO worth about $50 million. The company intends to use the money to further the development of torezolid phosphate and fund other clinical trials.

Key Executives and Contact Counts for Trius Therapeutics, Inc.

Identify and reach decision makers who have been verified by multiple contact methods.

Top Industries for Trius Therapeutics, Inc.

Need to reach more people? No problem.

  • Research more than 100 million people for titles, biographies, and more
  • Access more than 16 million contacts with email addresses and direct phone numbers
  • Call (866) 473-3932 to talk to a Business Information Consultant

Top Industries

Access comprehensive industry information to maximize campaign ROI.
View Industry Report

Company Size for Trius Therapeutics, Inc.

Select key company statistics to target your marketing resources.
View Company Report

Company Size  
2012 Employees 90
2012 Sales (mil) $27.185